Following the findings of the TACTI-002 trial, the FDA has given Eftilagimod alpha, when combined with pembrolizumab, a rapid-track designation as a first-line therapy for individuals with stage III B/IV NSCLC who have a PD-L1 TPS score of less than 1%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.